H. Heimpel

Randomized Comparison of Imatinib 400 Mg Vs. Imatinib + IFN Vs. Imatinib + AraC Vs. Imatinib after IFN Vs. Imatinib 800 Mg: Optimized Treatment and Survival. Designed First Interim Analysis of the German CML Study IV

Martin C. Müller, H. Heimpel, J. Hasford, 2008 .

Ex vivo T‐cell depletion with the monoclonal antibody Campath‐1 plus human complement effectively prevents acute graft‐versus‐host disease in allogeneic bone marrow transplantation

H. Heimpel, G. Hale, H. Waldmann, 1986, British journal of haematology.